Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK

被引：2
|
作者：
Dodkins, J. [1 ]
Cook, A. [1 ]
Nossiter, J. [1 ]
Payne, H. A. [2 ]
Clarke, N. W. [3 ]
van der Meulen, J. [4 ]
Aggarwal, A. [4 ]
机构：
[1] Royal Coll Surgeons England, Clin Effectiveness Unit, London, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, London, England
[3] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England
[4] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1790P
引用
收藏
页码：S967 / S967
页数：1
相关论文
共 50 条
  • [21] CONTEMPORARY TRENDS IN TREATMENT INTENSIFICATION FOR MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN 5 EUROPEAN COUNTRIES: RESULTS FROM PATIENT CHART REVIEWS
    Grossman, J.
    Chen, S.
    Goebell, P. J.
    VALUE IN HEALTH, 2024, 27 (06) : S375 - S375
  • [22] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    UROLOGIE, 2023, 62 (04): : 441 - 442
  • [23] A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
    Shore, Neal D.
    Morgans, Alicia K.
    Paracha, Noman
    Hodgkinson, Sarah
    Eichinger, Christian
    Millar, Craig
    Chen, Stephanie
    Boegemann, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 324 - 324
  • [24] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis
    Lambert, E.
    Hollebosch, S.
    van Praet, C.
    Van Bruwaene, S.
    Duck, L.
    De Roock, W.
    van Wambeke, S.
    Ghysel, C.
    Ameye, F.
    Schatteman, P.
    Vandenbroucke, F.
    Sautois, B.
    Baekelandt, F.
    Ost, D.
    Fransis, K.
    Filleul, B.
    Remondo, C.
    Wynendaele, W.
    Bamelis, B.
    Logghe, P.
    Vergauwe, E.
    Denies, E.
    Joniau, S.
    Lumen, N.
    ACTA CLINICA BELGICA, 2022, 77 (06) : 897 - 905
  • [26] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
  • [27] Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now
    McKay, Rana R.
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 45 : 41 - 43
  • [28] COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Sathianathen, Niranjan
    Lawrentschuk, Nathan
    Azad, Arun
    Konety, Badrinath
    Murphy, Declan
    JOURNAL OF UROLOGY, 2023, 209 : E492 - E492
  • [29] Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
    Palmbos, Phillip Lee
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia Katherine
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [30] ESTIMATING UTILITIES / DISUTILITIES FOR HIGH RISK METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) AND TREATMENT-RELATED ADVERSE EVENTS
    Hall, F.
    de Freitas, H. M.
    Kerr, C.
    Ito, T.
    Nafees, B.
    Lloyd, A. J.
    Penton, J.
    Hadi, M.
    Pham, T.
    VALUE IN HEALTH, 2017, 20 (09) : A448 - A448
12345